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In asthma, T helper 2 (TH2)-type cytokines such as interleukin 
(IL)-4, IL-5, and IL-13 are produced by activated CD4+ T cells. 
Dendritic cells played an important role in determining the 
fate of naïve T cells into either TH1 or TH2 cells. We 
determined whether RG-II regulates the TH1/TH2 immune 
response by using an ovalbumin-induced murine model of 
asthma. RG-II reduced IL-4 production but increased inter-
feron-gamma production, and inhibited GATA-3 gene 
expression. RG-II also inhibited asthmatic reactions including 
an increase in the number of eosinophils in bronchoalveolar 
lavage fluid, an increase in inflammatory cell infiltration in 
lung tissues, airway luminal narrowing, and airway hyperres-
ponsiveness. This study provides evidence that RG-II plays a 
critical role in ameliorating the pathogenic process of 
asthmatic inflammation in mice. These findings provide new 
insights into the immunotherapeutic role of RG-II in terms of 
its effects in a murine model of asthma. [BMB reports 2012; 
45(2): 79-84]
INTRODUCTION
Asthma is a chronic inflammatory disease affecting the airways 
that is characterized by recurring symptoms, including rever-
sible airflow obstruction and bronchospasm (1). Asthma epi-
sodes are thought to be caused by a combination of genetic 
and environmental factors such as allergens, tobacco smoke, 
and emotional stress (2, 3). As a model, ovalbumin (OVA)-in-
duced asthma is characterized by airway hyperresponsiveness 
(AHR) and airway inflammation (4), and is closely associated 
with the accumulation of eosinophils, neutrophils, and lym-
phocytes in the bronchial lumen and lung tissues (4). These 
cellular infiltrates release various chemical mediators capable 
of inducing AHR (5, 6). Additionally, recruitment of these in-
flammatory cells from the blood to sites of inflammation is re-
garded as a central event in the development and prolongation 
of airway inflammation (7). 
　The roots of P. ginseng are precious since the plant requires 
4-6 years to harvest, whereas the leaves can be harvested ev-
ery year. If the leaves of P. ginseng had similar pharmaco-
logical activity as the roots, much more of the therapeutic 
compounds could be available for clinical use. Previous stud-
ies have reported that polysaccharides from the leaves of P. 
ginseng possess potent anti-complementary (8) and anti-ulcer 
activities (9), indicating the potential clinical value of the 
leaves. 
　Antigen-activated CD4+ T cells are able to differentiate into 
different types of effector cells, each with distinct functional 
properties conferred by cytokines (10, 11). The T helper 2 
(TH2)-type cytokines interleukin-4 (IL)-4, IL-5, and IL-13, all of 
which are expressed by activated CD4+ T cells, have critical 
roles in the pathogenesis of asthma by controlling immuno-
globulin E (IgE) production, mast cell growth, as well as differ-
entiation and activation of mast cells and eosinophils (12, 13). 
In contrast, TH1 cytokines such as interferon-gamma (IFN-γ) 
and IL-12, which downregulate the TH2 response, inhibit the 
development of allergic lung inflammation (14, 15). Therefore, 
therapeutic interventions that simultaneously inhibit TH2 cyto-
kine production while enhancing TH1 cytokine production 
may be useful in treating allergic asthma (16). 
　GATA-3, a member of the GATA family of transcription fac-
tors, is a transcription factor that binds to the T cell re-
ceptor-alpha (TCR-α) gene enhancer (17). Specifically, GATA- 
3 is induced through the action of the STAT6 protein upon 
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Fig. 1. Effect of RG-II on airway responsiveness, lung inflamma-
tion, and inflammatory cell infiltration in OVA-treated mice. (A) 
Airway responsiveness was measured 24 hours after the final 
challenge in saline-inhaled mice administered PBS (CON), 
OVA-sensitized mice administered saline (OVA), OVA-sensitized 
mice administered a low dose of RG-II (20 mg/kg, RG-II/L), and 
OVA-sensitized mice administered a high dose of RG-II (100 
mg/kg, RG-II/H). Airway responsiveness to aerosolized methacho-
line was measured in unrestrained and conscious mice. Mice 
were placed into the main chamber and nebulized first with PBS, 
followed by increasing doses (2.5 to 50 mg/ml) of methacholine 
for 15 min for each nebulization. Readings of breathing parame-
ters were taken for 3 minutes after each nebulization, during 
which Penh values were determined. (B) Mice were sensitized 
and challenged as described above. Sections were obtained from 
the lungs of mice receiving control (CON), OVA (OVA), OVA 
plus a low dose of RG-II (RG-II/L), and OVA plus a high dose of 
RG-II (RG-II/H). Lungs were removed 24 hours after the final air-
way challenge. Sections were stained by haematoxylin and eosin, 
PAS, and Alcian blue (400×).
binding of IL-4 to its receptor and plays a critical role in regu-
lating TH1 and TH2 cell differentiation. GATA-3 specifically 
regulates TH2 cytokine expression at the transcriptional level 
by binding directly to the promoters of IL-5 and IL-13, as well 
as by affecting chromatin remodeling, resulting in opening of 
the IL-4 locus (18). The T-box transcription factor T-bet (Tbx21) 
has emerged as a key regulator of dendritic cells as well as the 
type 1 immune response, playing an essential role in establish-
ing effector cell fate in T and B lymphocytes (19). T-bet ex-
pression is induced in TH1 cell,s but not TH2 cells, upon signal 
transduction, and acts as a potent transactivator of the IFN-γ 
gene in TH1, NK, and B cells (20). Therefore, we investigated 
the effects of RG-II on T-bet and GATA-3 expression in a mur-
ine model of asthma.
　In this study, administration of RG-II before the final airway 
OVA challenge resulted in significant inhibition of asthmatic 
reactions, suggesting that RG-II could play a critical role in the 
improvement of the pathogenic processes of asthma in mice. 
RESULTS
RG-II inhibits AHR, lung inflammation, and inflammatory cell 
infiltration
Airway responsiveness was measured as a Penh value in re-
sponse to increasing doses of methacholine. In OVA-sensitized 
and -challenged mice, the dose-response curve of the Penh 
value was shifted to the left compared to that of control mice 
(Fig. 1A). In addition, the Penh value produced by methacho-
line administration (at doses ranging from 2.5-50 mg/ml) was 
significantly higher in the OVA-sensitized and -challenged 
mice compared to controls. In OVA-sensitized and -challenged 
mice treated with RG-II, the dose-response curve of the Penh 
value was shifted to the right compared to that of untreated 
OVA-sensitized and -challenged mice. Moreover, the shift was 
dose-dependent. 
　Histological analyses revealed the typical pathological fea-
tures of asthma in OVA-exposed mice compared to control 
mice, with the OVA-exposed mice displaying numerous in-
flammatory cells, including infiltrated eosinophils around the 
bronchioles (Fig. 1B). Mice treated with RG-II showed a 
marked decrease in inflammatory cell infiltration in the peri-
bronchiolar and perivascular regions (Fig. 1B). Therefore, the 
increases in total lung inflammation and cell infiltration were 
significantly inhibited by administration of RG-II. These results 
suggest that RG-II inhibits OVA-induced airway hyper-
responsiveness and antigen-induced inflammation in the lungs, 
including the influx of eosinophils.
RG-II reduces TH2 cytokine levels in lung tissues of OVA-se-
nsitized and -challenged mice
BAL fluids were obtained 24 hours after the final airway 
challenge. In the BAL fluids of mice subjected to airway chal-
lenge with OVA, the levels of IL-4, IL-5, and IL-13 were sig-
nificantly higher than those in control mice. Administration of 
RG-II reduced the secretion of IL-4 (Fig. 2A), IL-5 (Fig. 2B), and 
IL-13 (Fig. 2C). However, the levels of the TH2 cytokines IL-4, 
IL-5, and IL-13, as well as those of the TH1 cytokines IFN-γ 
(Fig. 2D) and IL-12 (Fig. 2E) were higher in OVA-sensitized 
and OVA-challenged mice compared to cytokine levels in sal-
ine-sensitized and -challenged control mice. These results in-
dicate that RG-II treatment reduces TH2 cytokine levels, such 
as IL-4, IL-5, and IL-13, in BAL fluids.
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Fig. 2. Effect of RG-II on TH1 and TH2 cytokine production. 
OVA-sensitized mice were treated as described in Materials and 
methods. BAL fluid was obtained 7 days after the final airway 
challenge as described by the manufacturer. IL-4 (A), IL-5 (B), IL-13 
(C), IFN-γ (D), and IL-12 (E) levels in the BAL fluid was measured 
by ELISA.
Fig. 4. Effect of RG-II on expression of GATA-3 and T-bet in the 
lungs of OVA-treated mice. Samples were obtained 7 days after 
challenge from mice treated with control (CON), OVA (OVA), 
OVA plus a low dose of RG-II (20 mg/kg, RG-II/L), or OVA plus 
a high dose of RG-II (100 mg/kg, RG-II/H) and then subjected to 
Western blot analysis with α-GATA-3 (A) and α-T-bet (B) antibody.
RG-II decreases IgE levels in the serum and the number of 
inflammatory cells in BAL fluid
Since TH2 cytokines promote airway inflammation in asthma 
by increasing IgE levels, which in turn favors the TH2 in-
flammatory pathway, we measured how much RG-II modu-
lates serum IgE levels in OVA-induced mice. As shown in Fig. 
3, serum IgE levels in OVA-induced mice were significantly 
higher compared to those in control mice. RG-II significantly 
decreased serum IgE levels (Fig. 3A), but not serum IgG2a lev-
els (Fig. 3B). These data indicate that RG-II modulates the 
TH1/TH2 balance towards TH1 in an OVA-induced asthma 
model. The numbers of total cells, eosinophils, lymphocytes, 
and macrophages in BAL fluid increased significantly 24 hours 
after OVA challenge compared to the numbers of cells after 
saline inhalation (Fig. 3C). These increases in the numbers of 
inflammatory cells were significantly inhibited by RG-II 
administration. 
RG-II reduces GATA-3 expression in lung tissues of OVA-sen-
sitized and -challenged mice
Western blot analysis showed that GATA-3 and T-bet ex-
pression was significantly increased in lung tissues 24 hours af-
ter OVA-challenge compared to control tissues. Administration 
of RG-II significantly inhibited this increase in GATA-3 ex-
pression (Fig. 4A). On the other hand, RG-II administration in-
duced an increase in T-bet expression (Fig. 4B).
DISCUSSION
This is first study to demonstrate that RG-II ameliorates airway 
inflammation in a murine model of asthma. Notably, RG-II 
profoundly inhibited asthmatic reactions, including leukocyte 
recruitment into the airway and lung inflammation. We also 
observed that RG-II regulates the TH1/TH2 balance by media-
ting the levels of T-bet and GATA3. 
　OVA-induced asthma is recognized as a disease caused by 
chronic airway inflammation, which is characteristically asso-
ciated with the infiltration of lymphocytes, eosinophils, and 
neutrophils into the bronchial lumen. Presently, we observed 
that OVA-induced asthma increased eosinophil infiltration, 
thickness of the bronchial wall, and surface area of smooth 
muscle. However, these events were significantly inhibited by 
administration of RG-II. T-bet, a member of the T-box family of 
transcription factors, is a master determinant of the TH1 cell 
lineage (20, 21). Indeed, T-bet-deficient mice lack the TH1 im-
mune response (22), which inhibits allergic responses (23, 24). 
Moreover, ectopic expression of T-bet in murine TH2 cells di-
rects activation of IFN-γ as well as upregulation of IL-12Rβ (25, 
26). On the other hand, GATA-3 belongs to the GATA family 
of transcription factors. Six members (GATA-1 to GATA-6) of 
this family have been identified in birds, and homologues 
have been found in both mammals and birds. Based on their 
expression profiles and structures, GATA proteins may be clas-
sified as either hematopoietic (GATA-1 to GATA-3) (27) or 
non-hematopoietic (GATA-4 to GATA-6). Naïve CD4+ T cells 
express low levels of GATA-3. However, the expression of 
GATA-3 is dependent upon T cell lineage; it is markedly upre-
gulated in cells differentiating along the TH2 pathway, whereas 
it is downregulated in cells differentiating along the TH1 path-
way (28). These data demonstrate that RG-II inhibits the in-
crease in GATA3 expression in OVA-sensitized and OVA-chal-
lenged mice (Fig. 4). Therefore, we can conclude that RG-II ad-
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Fig. 3. Effect of RG-II on IgE and IgG2a levels in serum of 
OVA-treated mice and the number of total cells and different cell 
types in BAL fluids of OVA-treated mice. Blood was collected by 
cardiac puncture, and serum IgE (A) and IgG2a (B) levels were 
measured. IgE and IgG2a levels were analyzed by using ELISA 
(n=5). (C) Mice were sensitized with OVA on days 0 and 14 by 
i.p. injection of OVA emulsified in 1 mg of aluminum hydroxide. 
Three days later, mice were treated with vehicle (CON), OVA 
(OVA), OVA plus a low dose of RG-II (20 mg/kg, RG-II/L), or 
OVA plus a high dose of RG-II (100 mg/kg, RG-II/H). The mice 
were challenged for 30 minutes with a 5% (w/v) OVA aerosol in 
saline (or saline alone as a control) using an ultrasonic nebulizer. 
The BAL cells were collected 24 hours after OVA challenge. The 
results shown are from a single representative experiment of the 
total five experiments performed. 
ministration is a novel, selective way to simultaneously sup-
press GATA-3 and increase T-bet expression in asthmatic re-
actions in vivo (29). 
　In addition, TH1 and TH2 cytokine production was examined 
in CD4+ T cells. RG-II inhibited the increase in the level of 
IL-4, a TH2 cytokine produced in OVA-sensitized and 
OVA-challenged mice. In contrast, RG-II increased the level of 
IFN-γ, a TH1 cytokine produced in mice administered RG-II. 
Taken together, these results strongly indicate that RG-II re-
duces allergic airway inflammation and hyperresponsiveness 
through modulation of the TH1/TH2 balance by suppressing 
GATA-3 expression and increasing T-bet expression. 
　In conclusion, these data suggest that RG-II might offer a 




Female, 6 to 8-week-old, BALB/c mice that were certified free 
of murine-specific pathogens were obtained from Charles 
River Laboratories (Yokohama, Japan). All experimental ani-
mals were maintained under a protocol approved by the 
Institutional Animal Care and Use Committee of Pusan 
National University Medical School.
Purification of RG-II 
A crude polysaccharide fraction (GL-2) was prepared from the 
leaves of Panax ginseng by hot water extraction, ethanol pre-
cipitation, and dialysis (8). GL-2 was fractionated by a Cetavlon 
(cetyltrimethylammonium bromide) precipitation, and a weakly 
acidic polysaccharide fraction (GL-4) was obtained. The Fc re-
ceptor expression-enhancing polysaccharide (RG-II) was puri-
fied from GL-4 by anion-exchange chromatography on DEAE 
Sepharose CL-6B as described previously (30). To remove the 
colored materials in the polysaccharide, RG-II was further puri-
fied on a Q-Sepharose column (C1- form). For this, the column 
was washed with water and eluted sequentially with 0.1, 0.2, 
0.3, 0.4, 0.5, and 1.0 M NaC1. The major fraction, which was 
eluted with 0.3 M NaC1, was further fractionated by gel filtra-
tion on a Bio-Gel P-30 column to obtain the purified GL-4IIb2 
(yield: 5.8 mg/kg dry leaves).
Experimental protocol
Mice were sensitized intraperitoneally (i.p.) with 20 μg of 
OVA (Sigma-Aldrich, St. Louis, MO, USA) emulsified in 25 μl 
of aluminum hydroxide (Pierce, Rockford, IL, USA) on days 0 
and 14. Mice were challenged for 30 min with OVA (5%) via 
the airway from days 20 to 22. Brochoalveolar lavage (BAL) 
fluid was obtained 24 hours after the final challenge. At the 
time of lavage, the mice (five mice from each group) were kil-
led using an overdose of ether. The chest cavity was exposed 
to allow expansion, after which the trachea was carefully in-
cubated and the catheter secured with ligatures. Pre-warmed 
saline solution was then slowly infused into the lungs and 
withdrawn. The aliquots were pooled and stored at 4oC. A por-
tion of each pooled aliquot was then centrifuged, and the su-
pernatants were kept at −70oC until use.
Administration of RG-II
Female BALB/c mice were injected i.p. with 20 mg/kg/day or 
100 mg/kg/day of RG-II (in a 200 μl volume) everyday from 
days 17 to 19.
Total cell counting
Total cell numbers were counted with a hemocytometer. 
Smears of BAL cells prepared with Cytospin II (Shandon, 
Runcorn, UK) were stained with Diff-Quick solution (Merck, 
Darmstadt, Germany) for differential cell counting. Two in-
dependent and blinded investigators counted the cells using a 
microscope. Approximately 200 cells were counted in each of 
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Twenty-four hours after the final challenge, lungs were re-
moved from the mice following sacrifice. Prior to lung re-
moval, the lungs and trachea were filled by intratracheal ad-
ministration of a fixative (4% paraformaldehyde) using a liga-
ture around the trachea. Lung tissues were then fixed with 
10% (v/v) paraformaldehyde. The specimens were dehydrated 
and embedded in paraffin. For histological examination, 4 
μm-thick sections of fixed and embedded tissues were cut on a 
Leica model 2165 rotary microtome (Leica, Nussloch, 
Germany), placed on glass slides, deparaffinized, and sequen-
tially stained with hematoxylin 2 and eosin-Y (Richard-Allan 
Scientific, Kalamazoo, MI, USA). To identify mucus-producing 
cells, lung sections were stained with periodic acid-Schiff 
(PAS) and Alcian blue (AB).
Determination of airway responsiveness to methacoline
Airway responsiveness in mice was measured 24 hours after 
the final challenge in an unrestrained conscious state, as pre-
viously described (9). Mice were placed in a barometric ple-
thysmographic chamber (All Medicus, Seoul, Korea), and base-
line readings were taken for 3 minutes and then averaged. 
Aerosolized methacholine at various concentrations (2.5 to 50 
mg/ml) was nebulized through an inlet of the main chamber. 
Enhanced pause (Penh), which was calculated according to the 
manufacturer’s protocol as (expiratory time/relaxation time-1) 
×(peak expiratory flow/peak inspiratory flow), is a dimension-
less value that is a function of the proportion of maximal ex-
piratory to maximal inspiratory box pressure signals and a 
function of the timing of expiration. In this study, Penh was 
used as a measure of airway responsiveness to methacholine. 
Results are expressed as the percent increase in Penh follow-
ing challenge with each concentration of methacholine, and 
the baseline Penh (after saline challenge) was set to 100%. 
Penh values taken for 3 minutes following each nebulization 
were averaged and evaluated.
Measurement of cytokines
Cytokine levels in BAL fluid was determined by enzyme-linked 
immunosorbent assay (ELISA). ELISA kits from R&D Systems 
(Minneapolis, MN, USA) were employed for the measurement 
of IL-4, IL-5, IL-13, IL-12, and IFN-γ.
Western blot analysis
The lung tissues were homogenized, washed with phos-
phate-buffered saline (PBS), and incubated in lysis buffer con-
taining a protease inhibitor cocktail (Sigma-Aldrich) to obtain 
extracts of lung and spleen proteins. The samples were loaded 
onto 10% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis gels and the separated proteins were electrotrans-
ferred to polyvinylidene difluoride membranes. The blots were 
incubated with anti-GATA-3 antibody or anti-T-bet antibody 
overnight at 4oC. After washing, the blots were next incubated 
with horseradish peroxidase-conjugated secondary antibody. 
Following three washes with Tris-buffered saline containing 
Tween-20, immunoreactive bands were visualized using an 
enhanced chemiluminescence detection system. 
Measurement of OVA-specific serum IgE levels
OVA-specific serum IgE levels were determined in samples 
collected 24 hours after the final OVA challenge using ELISA. 
Briefly, a 96-well microtiter plate was coated with OVA (10 
mg/ml), followed by incubation with mouse sera and then bio-
tin-conjugated rat anti-mouse IgE (Pharmingen, San Diego, CA, 
USA). Then, avidin-horseradish peroxidase solution was added 
to each well. Units are shown as optical density readings at 
405 nm.
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